Notice is given under section 14(1) of the Agricultural Compounds and Veterinary Medicines Act 1997 (“Act”), of the following application to vary the conditions of a registered trade name product under section 9(2) of the Act:

Trade Name: NEXGARD Chewables for Dogs

Reference: A011040

Active Ingredients and Concentrations:

Each 0.5g chewable contains 11. mg afoxolaner for dogs 2–4kg
Each 1.25g chewable contains 28.3mg afoxolaner for dogs 4.1–10kg
Each 3g chewable contains 68.0mg afoxolaner for dogs 10.1–25kg
Each 6g chewable contains 136.0mg afoxolaner for dogs 25.1–50kg

Formulation Type: Tablet

Application Method / Administration Route: Oral

Existing Use Claim:

NEXGARD Chewables kills adult fleas and is indicated for the treatment and prevention of flea (Ctenocephalides spp.) infestations and for the control of NZ cattle tick (Haemaphysalis longicornis) for 5 weeks (35 days). Following administration, fleas are killed within 6–8 hours. Effective flea control with NEXGARD Chewables also prevents flea tapeworm (Dipylidium caninum) infestation.

It also treats and controls demodectic mange caused by Demodex spp., sarcoptic mange caused by Sarcoptes scabiei and ear mite (Otodectes cynotis) infestations.

Proposed New Claim:

NEXGARD Chewables kills adult fleas and is indicated for the treatment and prevention of flea (Ctenocephalides spp.) infestations and for the control of NZ cattle tick (Haemaphysalis longicornis) for 5 weeks (35 days). Following administration, fleas are killed within 6–8 hours. Effective flea control with NEXGARD Chewables also prevents flea tapeworm (Dipylidium caninum) infestation.

It also treats and controls demodectic mange caused by Demodex spp., sarcoptic mange caused by Sarcoptes scabiei and ear mite (Otodectes cynotis) infestations.

Treats and controls biting lice (Trichodectes canis).

Any person may make a written submission to the director-general concerning this application.

Under sections 16 and 17 of the Act, a written submission:

1. must state in full the reasons for making the submission;
2. may state any decision sought on that application; and
3. must be received by the director-general no later than 30 working days after the date of this notice.

Each submission must state the trade name product(s) to which it relates. Under section 18 of the Act, a copy of every submission will be forwarded to the applicant.

The following address is:

1. where submissions on this application are to be sent;
2. where requests for copies of the public information relating to the application can be sent;
3. where public information relating to the application can be viewed; and
4. the director-general’s address for service:

ACVM Team, Ministry for Primary Industries, Charles Fergusson Building, 38–42 Bowen Street, Pipitea, Wellington 6011. Postal Address: PO Box 2526, Wellington 6140. Email: acvm.consultation@mpi.govt.nz.

MPI encourages submission by email.

The applicant’s address for service is:

Boehringer Ingelheim Animal Health New Zealand Limited, Level 2, 3 Te Kehu Way, Mount Wellington, Auckland 1060. Postal Address: PO Box 76211, Manukau, Auckland 2241.

Dated at Wellington this 27th day of November 2024.

SHALEEN NARAYAN, Manager Approvals, Ministry for Primary Industries (acting under delegated authority).